Genmab A/S (GMAB) to Release Earnings on Wednesday

Genmab A/S (NASDAQ:GMAB) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of $0.44 per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 12, 2026 at 12:00 PM ET.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.48 by $0.17. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $975.40 million. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $33.03 on Wednesday. The business has a 50-day moving average of $32.55 and a two-hundred day moving average of $29.31. The company has a market capitalization of $21.22 billion, a price-to-earnings ratio of 14.06, a price-to-earnings-growth ratio of 19.53 and a beta of 0.90. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $35.43.

Analyst Ratings Changes

A number of equities analysts recently issued reports on GMAB shares. Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Truist Financial restated a “buy” rating and set a $48.00 price objective (down previously from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 target price on shares of Genmab A/S in a research report on Wednesday, January 28th. Weiss Ratings reiterated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.25.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Paradigm Biocapital Advisors LP purchased a new stake in Genmab A/S during the 3rd quarter valued at approximately $117,063,000. Orbis Allan Gray Ltd increased its holdings in shares of Genmab A/S by 38.7% in the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock valued at $163,635,000 after purchasing an additional 2,209,659 shares during the period. Deep Track Capital LP purchased a new stake in shares of Genmab A/S during the third quarter worth approximately $14,760,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Genmab A/S by 5.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,643,139 shares of the company’s stock worth $111,735,000 after purchasing an additional 188,761 shares during the period. Finally, Squarepoint Ops LLC grew its position in Genmab A/S by 636.3% in the 2nd quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock valued at $1,947,000 after buying an additional 81,434 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.